Maarsingh Harm, Leusink John, Bos I Sophie T, Zaagsma Johan, Meurs Herman
Department of Molecular Pharmacology, Centre for Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Respir Res. 2006 Jan 12;7(1):6. doi: 10.1186/1465-9921-7-6.
Using guinea pig tracheal preparations, we have recently shown that endogenous arginase activity attenuates inhibitory nonadrenergic noncholinergic (iNANC) nerve-mediated airway smooth muscle relaxation by reducing nitric oxide (NO) production--due to competition with neuronal NO-synthase (nNOS) for the common substrate, L-arginine. Furthermore, in a guinea pig model of allergic asthma, airway arginase activity is markedly increased after the early asthmatic reaction (EAR), leading to deficiency of agonist-induced, epithelium-derived NO and subsequent airway hyperreactivity. In this study, we investigated whether increased arginase activity after the EAR affects iNANC nerve-derived NO production and airway smooth muscle relaxation.
Electrical field stimulation (EFS; 150 mA, 4 ms, 4 s, 0.5-16 Hz)-induced relaxation was measured in tracheal open-ring preparations precontracted to 30% with histamine in the presence of 1 microM atropine and 3 microM indomethacin. The contribution of NO to EFS-induced relaxation was assessed by the nonselective NOS inhibitor Nomega-nitro-L-arginine (L-NNA, 100 microM), while the involvement of arginase activity in the regulation of EFS-induced NO production and relaxation was investigated by the effect of the specific arginase inhibitor Nomega-hydroxy-nor-L-arginine (nor-NOHA, 10 microM). Furthermore, the role of substrate availability to nNOS was measured in the presence of exogenous L-arginine (5.0 mM).
At 6 h after ovalbumin-challenge (after the EAR), EFS-induced relaxation (ranging from 3.2 +/- 1.1% at 0.5 Hz to 58.5 +/- 2.2% at 16 Hz) was significantly decreased compared to unchallenged controls (7.1 +/- 0.8% to 75.8 +/- 0.7%; P < 0.05 all). In contrast to unchallenged controls, the NOS inhibitor L-NNA did not affect EFS-induced relaxation after allergen challenge, indicating that NO deficiency underlies the impaired relaxation. Remarkably, the specific arginase inhibitor nor-NOHA normalized the impaired relaxation to unchallenged control (P < 0.05 all), which effect was inhibited by L-NNA (P < 0.01 all). Moreover, the effect of nor-NOHA was mimicked by exogenous L-arginine.
The results clearly demonstrate that increased arginase activity after the allergen-induced EAR contributes to a deficiency of iNANC nerve-derived NO and decreased airway smooth muscle relaxation, presumably via increased substrate competition with nNOS.
我们最近利用豚鼠气管制备物发现,内源性精氨酸酶活性通过减少一氧化氮(NO)生成来减弱抑制性非肾上腺素能非胆碱能(iNANC)神经介导的气道平滑肌舒张——这是由于与神经元型一氧化氮合酶(nNOS)竞争共同底物L-精氨酸所致。此外,在过敏性哮喘豚鼠模型中,早期哮喘反应(EAR)后气道精氨酸酶活性显著增加,导致激动剂诱导的、上皮来源的NO缺乏以及随后的气道高反应性。在本研究中,我们调查了EAR后增加的精氨酸酶活性是否影响iNANC神经源性NO生成和气道平滑肌舒张。
在1 microM阿托品和3 microM吲哚美辛存在的情况下,对用组胺预收缩至30%的气管开环制备物测量电场刺激(EFS;150 mA,4 ms,4 s,0.5 - 16 Hz)诱导的舒张。通过非选择性NOS抑制剂Nω-硝基-L-精氨酸(L-NNA,100 microM)评估NO对EFS诱导舒张的作用,同时通过特异性精氨酸酶抑制剂Nω-羟基-L-精氨酸(nor-NOHA,10 microM)的作用研究精氨酸酶活性在调节EFS诱导的NO生成和舒张中的作用。此外,在存在外源性L-精氨酸(5.0 mM)的情况下测量底物可用性对nNOS作用的影响。
卵清蛋白激发后6小时(EAR后),EFS诱导的舒张(0.5 Hz时为3.2±1.1%至16 Hz时为58.5±2.2%)与未激发的对照相比显著降低(7.1±0.8%至75.8±0.7%;所有P<0.05)。与未激发的对照相反,NOS抑制剂L-NNA在变应原激发后不影响EFS诱导的舒张,表明NO缺乏是舒张受损的原因。值得注意的是,特异性精氨酸酶抑制剂nor-NOHA使受损的舒张恢复到未激发对照水平(所有P<0.05),该作用被L-NNA抑制(所有P<0.01)。此外,外源性L-精氨酸模拟了nor-NOHA的作用。
结果清楚地表明,变应原诱导的EAR后增加的精氨酸酶活性导致iNANC神经源性NO缺乏和气道平滑肌舒张减少,推测是通过增加与nNOS的底物竞争。